Millipore Sigma Vibrant Logo

189510 Autotaxin Inhibitor I, S32826 - CAS 1103672-43-0 - Calbiochem

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
1103672-43-0C₂₁H₃₄NO₄PNa₂ • 2H₂O

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
189510-5MG
Comprobando disponibilidad...
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      Frasco de vidrio 5 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      Solicitar precio
      Description
      OverviewA phosphonate compound that potently inhibits both the phosphodiesterase (IC50 = 9 nM in pNppp assay using ATX β) and the lysoPLD (IC50 = 5.6 nM and 47 nM, by enzyme-linked fluorescence detection or autoradiography by TLC, respectively, using ATX β) activities of ATX α/β/γ, while exhibiting much reduced (IC50 ~ 6 µM and 15 µM against Src and PTP-1B, respectively) or little activity toward 29 other receptors and enzymes. Shown to block LPA release from murine 3T3F422A adipocytes (IC50 = 90 nM) in vitro and from excised human and rat adipose tissues (by ~70% inhibition at 0.2 and 1 µM, respectively) in cultures ex vivo. The in vivo applicability of S32826 is limited by its low epithelial permeability and other poor pharmacokinetic properties. CTAB (Cat. No. 219374) is reported to counteract the inhibitory activity of S32826, 2-methyl-2,4-pentanediol can be used instead to stabilize purified enzyme in solution during S32826 inhibition assays.
      Catalogue Number189510
      Brand Family Calbiochem®
      SynonymsATX Inhibitor I, (4-(Tetradecanoylamino)benzyl)phosphonic acid disodium, dihydrate
      References
      ReferencesBoutin, J.A., and Ferry, G. 2009. Cell Mol. Life Sci. 66, 3009.
      Samadi, N., et al. 2009. Oncogene 28, 1028.
      Ferry, G., et al. 2008. J. Pharm. Exp. Ther. 327, 809.
      Product Information
      CAS number1103672-43-0
      FormWhite powder
      Hill FormulaC₂₁H₃₄NO₄PNa₂ • 2H₂O
      Chemical formulaC₂₁H₃₄NO₄PNa₂ • 2H₂O
      Hygroscopic Hygroscopic
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Regulatory Review
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      189510-5MG 04055977221862

      Documentation

      Autotaxin Inhibitor I, S32826 - CAS 1103672-43-0 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Autotaxin Inhibitor I, S32826 - CAS 1103672-43-0 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      189510

      Referencias bibliográficas

      Visión general referencias
      Boutin, J.A., and Ferry, G. 2009. Cell Mol. Life Sci. 66, 3009.
      Samadi, N., et al. 2009. Oncogene 28, 1028.
      Ferry, G., et al. 2008. J. Pharm. Exp. Ther. 327, 809.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision08-March-2011 RFH
      SynonymsATX Inhibitor I, (4-(Tetradecanoylamino)benzyl)phosphonic acid disodium, dihydrate
      DescriptionA phosphonate compound that potently inhibits both the phosphodiesterase (IC50 = 9 nM in pNppp assay using ATX β) and the lysoPLD (IC50 = 5.6 nM and 47 nM, by enzyme-linked fluorescence detection or autoradiography by TLC, respectively, using ATX β) activities of ATX α/β/γ, while exhibiting much reduced (IC50 ~6 µM and 15 µM against Src and PTP-1B, respectively) or little activity toward 29 other receptors and enzymes. Shown to block LPA release from murine 3T3F422A adipocytes (IC50 = 90 nM) in vitro and from excised human and rat adipose tissues (by ~70% inhibition at 0.2 and 1 µM, respectively) in cultures ex vivo. The in vivo applicability of S32826 is limited by its low epithelial permeability and other poor pharmacokinetic properties. CTAB (Cat. No. 219374) is reported to counteract the inhibitory activity of S32826, 2-methyl-2,4-pentanediol can be used instead to stabilize purified enzyme in solution during S32826 inhibition assays.
      FormWhite powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number1103672-43-0
      Chemical formulaC₂₁H₃₄NO₄PNa₂ • 2H₂O
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityH₂O (0.5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Regulatory Review
      ReferencesBoutin, J.A., and Ferry, G. 2009. Cell Mol. Life Sci. 66, 3009.
      Samadi, N., et al. 2009. Oncogene 28, 1028.
      Ferry, G., et al. 2008. J. Pharm. Exp. Ther. 327, 809.